Crossmark

Cost analysis on the use of rituximab and calcineurin inhibitors in children and adolescents with steroid-dependent nephrotic syndrome

Crossref DOI link: https://doi.org/10.1007/s00467-017-3789-y

Published Online: 2017-09-01

Published Print: 2018-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Iorember, Franca

Aviles, Diego

Kallash, Mahmoud

Bamgbola, Oluwatoyin
License Information

Text and Data Mining valid from 2017-09-01
More Information

Article History

Received: 17 June 2017

Revised: 14 August 2017

Accepted: 16 August 2017

First Online: 1 September 2017

Compliance with ethical standards

:

: The authors declare that they have no conflict of interest.